Dejan Milentijevic | Pharmacoeconomics | United States Published on 20/09/2025 by Academic Awards Dr. Dejan Milentijevic | Pharmacoeconomics | United States Janssen Pharmaceuticals | United States Dr. Dejan Milentijevic is a dynamic and accomplished Health Economics and Outcomes Research (HEOR) Executive with extensive experience in delivering actionable insights and driving strategic decision-making across the pharmaceutical, biotech, and medical device sectors. Renowned for his expertise in oncology, immunology, cardiovascular, and gene therapies, he excels at navigating complex therapeutic landscapes to enhance market access and inform healthcare policy. He skillfully integrates economic modeling, observational studies, real-world evidence, and patient-centered outcomes to optimize payer engagement, guide product launches, and improve patient outcomes. At Johnson & Johnson, he has led transformative initiatives in neuroscience, gene therapy, and cardiovascular portfolios, leveraging cross-functional collaboration, innovative data analytics, and AI-driven approaches to generate evidence supporting lifecycle management and value-based agreements. His prior roles at Celgene Corporation and Market Access Solutions further demonstrate his leadership in real-world evidence generation, budget impact modeling, and strategic market access planning. Dr. Dejan Milentijevic holds a Ph.D. in Biomedical Sciences from Weill Cornell Medical College, an MBA from Rutgers Business School, and advanced technical proficiency in SAS, SPSS, Python, and R statistical programming. With 750 citations, 31 published documents, and an h-index of 12, his research has significantly influenced payer decisions, scientific publications, and healthcare outcomes, underscoring his exceptional impact and ongoing contributions to evidence-based healthcare. Profile: Scopus | Orcid Featured Publications Milentijevic, D., Lin, J. H., Chen, Y.-W., Kogan, E., Shrivastava, S., Sjoeland, E., & Alberts, M. (2021). Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin. Journal of Medical Economics. Khorana, A. A., McCrae, K., Milentijevic, D., McCormick, N., Laliberté, F., Crivera, C., Lefebvre, P., Lejeune, D., Rozjabek, H., Schein, J., et al. (2019). The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation. American Journal of Hematology. Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Lejeune, D., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). An answer to “anticoagulant treatment of cancer‐associated venous thromboembolism: Interpreting real‐world data with caution.” American Journal of Hematology. Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Fortier, J., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. American Journal of Hematology.
Dr. Dejan Milentijevic is a dynamic and accomplished Health Economics and Outcomes Research (HEOR) Executive with extensive experience in delivering actionable insights and driving strategic decision-making across the pharmaceutical, biotech, and medical device sectors. Renowned for his expertise in oncology, immunology, cardiovascular, and gene therapies, he excels at navigating complex therapeutic landscapes to enhance market access and inform healthcare policy. He skillfully integrates economic modeling, observational studies, real-world evidence, and patient-centered outcomes to optimize payer engagement, guide product launches, and improve patient outcomes. At Johnson & Johnson, he has led transformative initiatives in neuroscience, gene therapy, and cardiovascular portfolios, leveraging cross-functional collaboration, innovative data analytics, and AI-driven approaches to generate evidence supporting lifecycle management and value-based agreements. His prior roles at Celgene Corporation and Market Access Solutions further demonstrate his leadership in real-world evidence generation, budget impact modeling, and strategic market access planning. Dr. Dejan Milentijevic holds a Ph.D. in Biomedical Sciences from Weill Cornell Medical College, an MBA from Rutgers Business School, and advanced technical proficiency in SAS, SPSS, Python, and R statistical programming. With 750 citations, 31 published documents, and an h-index of 12, his research has significantly influenced payer decisions, scientific publications, and healthcare outcomes, underscoring his exceptional impact and ongoing contributions to evidence-based healthcare. Profile: Scopus | Orcid Featured Publications Milentijevic, D., Lin, J. H., Chen, Y.-W., Kogan, E., Shrivastava, S., Sjoeland, E., & Alberts, M. (2021). Healthcare costs before and after stroke in patients with non-valvular atrial fibrillation who initiated treatment with rivaroxaban or warfarin. Journal of Medical Economics. Khorana, A. A., McCrae, K., Milentijevic, D., McCormick, N., Laliberté, F., Crivera, C., Lefebvre, P., Lejeune, D., Rozjabek, H., Schein, J., et al. (2019). The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation. American Journal of Hematology. Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Lejeune, D., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). An answer to “anticoagulant treatment of cancer‐associated venous thromboembolism: Interpreting real‐world data with caution.” American Journal of Hematology. Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Fortier, J., Nelson, W. W., Laliberté, F., Crivera, C., Lefebvre, P., Schein, J., et al. (2018). Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. American Journal of Hematology.